Cypromin

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cypromin

Quick Facts

Property Description
Active ingredient Cyproheptadine hydrochloride
Form Tablet, Syrup
Pharmacological class First-generation Antihistamine, Serotonin Antagonist
Common use Allergic conditions, Appetite stimulation
Origin Synthetic compound

Cypromin is defined as a prescription-only medication containing the single active ingredient, Cyproheptadine hydrochloride, which is a synthetic compound chemically classified as a Piperidine derivative. It belongs primarily to the First-generation Antihistamine class, but is distinctly characterized by its simultaneous function as a potent Serotonin Antagonist. This dual mechanism is delivered via the oral route in two primary dosage form(s): a solid tablet and an aqueous-based syrup.

The core of Cypromin's function is to serve as a therapeutic agent for systemic modulation of biological mediators. As an H1-receptor antagonist, it executes Histamine receptor blockade, thereby effectively counteracting the effects of histamine released during allergic conditions. This specific action establishes the agent's role in managing systemic allergic responses.

Furthermore, its unique secondary role as an antiserotonergic agent provides an additional systemic benefit. Due to this powerful Serotonin antagonism, the drug is clinically recognized for its utility in appetite stimulation. This specific action is associated with a central effect that can promote an increase in caloric intake. Cypromin's overall purpose is to mitigate distress caused by inflammatory mediators and provide systemic support, often serving as a tool for physicians in managing nutritional deficiencies associated with reduced appetite. The availability of the sweet-tasting syrup form distinguishes its use, making it a viable option for pediatric patients who may have difficulty swallowing tablets.

Regulatory References

  1. NIH MedlinePlus Drug Information on Cyproheptadine
  2. DailyMed Label for Cyproheptadine Syrup (NIH/NLM)

What side effects are possible with Cypromin?

Possible Side Effects and Safety Information

The safety profile of Cypromin, which contains the active ingredient Cyproheptadine hydrochloride, is formally characterized in government regulatory documents. The most prevalent adverse effects are associated with its action on the Central Nervous System and are often classified as common in frequency, per regulatory standards.

The most frequently reported reactions include sedation and sleepiness (somnolence), which are often noted as transient effects that may lessen with continued administration. Other documented neurological effects are dizziness, disturbed coordination, headache, and sometimes a paradoxical excitation in pediatric patients.

Adverse reactions are formally grouped by System-Organ Classes. Effects on the Digestive System often include dryness of the mouth, nausea, vomiting, and changes in bowel habits (diarrhea or constipation). The official label also lists increased appetite and resulting weight gain as potential effects.

Serious, though rare, adverse reactions affecting the Hematologic System include agranulocytosis, hemolytic anemia, and thrombocytopenia. Severe events affecting the Liver (Hepatic System) include hepatic failure and jaundice. Other serious events documented include convulsions (seizures) and anaphylactic shock.

Safety constraints apply to specific populations. The medicine is contraindicated in newborn or premature infants. Regulatory labeling states that older adults are more likely to experience dizziness, sedation, and hypotension. Furthermore, the use of Cypromin is contraindicated in patients receiving Monoamine Oxidase Inhibitor (MAOI) therapy due to the potential to intensify anticholinergic effects.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documentation requires that immediate medical attention be sought for all suspected or confirmed cases of Cypromin (cyproheptadine) overdose, or that emergency services be contacted without delay. The management approach is defined as symptomatic and supportive, as no specific antidote is known for this compound.

Overdose manifestations are documented to range from severe Central Nervous System (CNS) depression (leading to somnolence and coma) to CNS stimulation (including agitation, hallucinations, and convulsions). Severe overdose is associated with critical, life-threatening systemic outcomes, including cardiovascular collapse, hypotension, and respiratory arrest.


Documented Overdose Considerations

Category Regulatory Statement
Pediatric Risk Infants and young children are explicitly noted to be at a higher risk for severe outcomes, particularly CNS excitation and respiratory and cardiac arrest following overdose.
Anticholinergic Signs Clinical signs include severe anticholinergic effects such as mydriasis (dilated pupils), dry mouth, and hyperpyrexia (fever).
Emergency Procedures Official instructions for management may include initial procedures like gastric lavage or the use of activated charcoal, and continuous monitoring of vital signs and ECG in a hospital setting.

All individuals who exhibit any severe CNS or anticholinergic signs must seek urgent medical attention immediately, as prescribed by governmental health authorities.

Therapeutic Uses of Cypromin

What Cypromin Treats: Main Uses and Benefits

The medication is commonly used to help manage two distinct therapeutic domains: symptoms related to inflammatory or irritative states, as well as to address inadequate food intake. Its therapeutic scope is relevant for conditions associated with acute or disruptive episodes that cause systemic or localized discomfort, including the easing of symptoms related to inflammatory states and the management of nutritional intake concerns.

This medicine is applied in clinical settings that involve acute or unstable symptom patterns where symptoms linked to organ-specific functional stress are present. It plays a role in managing symptoms that interfere with daily comfort, encompassing conditions such as perennial and seasonal allergic rhinitis, allergic conjunctivitis, urticaria (hives), and cases of appetite loss leading to low body mass.

The use of Cypromin is primarily applied in scenarios where additional symptomatic support is needed for these conditions. It generally provides support that helps ease the overall symptom burden and contributes to improved comfort during periods of heightened distress.


Quick Fact: Relief for Pruritus and Anorexia

Cypromin is commonly used to help with persistent allergic itching (pruritus) and is applied in addressing appetite loss in patients who may be part of symptomatic management for inadequate food intake. It supports the patient during difficult episodes by easing distress.

Regulatory References

  1. Health Canada labelling standards

Eligibility and Restrictions for Use

Who Can and Cannot Use Cypromin?

This section defines population eligibility for Cypromin (Cyproheptadine) based strictly on official regulatory labeling.


Contraindicated Populations

Cypromin use is absolutely contraindicated for several groups, as stated in official regulatory documents. Individuals who must not use this medicine include:

  • Newborn or premature infants and nursing mothers.
  • Elderly or debilitated patients.
  • Patients currently receiving Monoamine Oxidase (MAO) Inhibitor therapy.
  • Patients with Angle-closure glaucoma or Stenosing peptic ulcer.
  • Individuals with obstructive conditions, such as Symptomatic prostatic hypertrophy, Bladder neck obstruction, or Pyloroduodenal obstruction.

Age and Conditional Use

Eligibility Group Regulatory Status
Children under 2 years Safety and efficacy have not been established (Not recommended).
Children 2 years and older Approved for use (Established safety/efficacy).
Pregnancy Use only if clearly needed.

Use requires caution in patients with pre-existing conditions like bronchial asthma, hyperthyroidism, hypertension, or increased intraocular pressure. Patients with renal insufficiency may require close monitoring.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Cypromin (Cyproheptadine hydrochloride) interactions are classified based on officially documented risks of combined pharmacodynamic effects and specific prohibitions found in regulatory documents.


Official Interaction Statements

Classification Interacting Agents Regulatory Constraint
Contraindicated Combination Monoamine Oxidase Inhibitors (MAOIs) Co-administration is formally prohibited due to the risk of prolonging and intensifying anticholinergic effects.
Additive CNS Effects Central Nervous System (CNS) Depressants (including hypnotics, sedatives, tranquilizers) and Alcohol Co-administration may result in additive CNS depression, including increased sedative effects.
Pharmacodynamic Antagonism Serotonergic Agents (e.g., Fluoxetine) Potential for antagonism of the serotonergic agent's effects, as documented in professional monographs.

Additional Interaction Context

  • Other Anticholinergics may lead to intensified anticholinergic effects when co-administered.
  • The medicine may suppress the results of antigen or histamine skin tests and should be considered if testing is scheduled.
  • Population Susceptibility: The drug is more likely to cause significant dizziness, sedation, and hypotension in Elderly, debilitated patients, a factor exacerbated by co-administration with other CNS agents.
  • Timing Rules: No specific mandatory time separation between doses is formally documented for co-administered substances.

This structure reflects the regulatory documentation, defining the necessary restrictions and considerations when co-administering Cypromin with other medicinal products or substances.

Mechanism of Action

How Cyproheptadine Works

Cyproheptadine hydrochloride's action is defined by its function as a non-selective antagonist that interferes with key signaling across several neurotransmitter systems, impacting both central and peripheral physiology simultaneously.

Antagonism of Histamine H1-Receptor Signaling

This mechanism is centered on the competitive antagonism of Histamine H1-receptors located on peripheral cells and central neurons. By blocking the binding of endogenous histamine, the molecule interrupts the signaling cascade that normally leads to processes like increased capillary permeability and sensory nerve activation, thereby limiting the downstream effects of histamine receptor activation.


Central Modulation of Appetite and Satiety Signaling

The molecule’s ability to cross the blood-brain barrier facilitates its antagonism of Serotonin 5-HT2A and 5-HT2C receptors in the hypothalamus. This action removes an inhibitory signal within the feeding center, functionally shifting the central balance toward an orexigenic signaling pattern.


CNS Arousal and Autonomic Function Modulation

This domain covers the drug's non-selective affinity for other targets, including central Histamine H1-receptors and Muscarinic M1-receptors. Central H1 blockade depresses the histaminergic wakefulness pathway, leading to reduced activity in that system, while M1-receptor antagonism inhibits parasympathetic tone, resulting in reduced glandular output and diminished smooth muscle contraction.

Dosage and Administration Information

Cypromin is designated for oral administration only, utilizing either the 4 mg tablet or the aqueous 2 mg/5 mL syrup formulation. The dosing framework suggests that the total daily amount be administered in divided doses throughout the day, typically two or three times, because the effect of a single dose lasts approximately 4 to 6 hours.

For adults, treatment typically begins with an initial dose of 4 mg taken three times daily. The established therapeutic range for maintenance is generally 12 mg to 16 mg per day, though the dose must be individualized based on response, and the total amount should not exceed 32 mg daily for any patient.

Usage instructions provide specific guidelines for particular populations. The medication is not established for children under the age of 2 years. For older children, distinct maximum daily limits are set: 12 mg for those aged 2 to 6 years and 16 mg for children aged 7 to 14 years. Administration may occur without regard to meal timing. Furthermore, a dose reduction is required for patients with documented hepatic impairment, and lower doses are suggested for those with renal insufficiency.

Recent Clinical Evidence

Research evidence / Overview of studies for Cypromin


Evidence for Use in Allergic Conditions

The research base for Cypromin's use in allergic conditions, such as allergic rhinitis (hay fever), hives (urticaria), and generalized itching (pruritus), draws primarily from historical and modern Randomized Controlled Trials (RCTs) and systematic reviews. Research was conducted in populations with conditions characterized by fluctuating or episodic manifestations and was applied in studies focusing on episodes where symptoms become more noticeable.

Researchers primarily monitored patient-reported outcomes describing perceived discomfort and used validated scales to measure changes in specific allergic symptoms. Studies monitored symptom patterns in the observed populations, which included both adults and pediatric patients experiencing these symptoms. Comparative evidence is lacking for Cypromin against many of the newer, second-generation antihistamines. Additionally, the influence of the drug's known central nervous system effects (such as sedation) on the reporting of subjective outcomes remains a limitation in some study reports.

Study Focus: Symptom Change and Quality of Life

This sub-section details the specific outcomes measured in the trials, such as the assessment of allergic symptoms and the assessment of patient-reported comfort levels. Studies exploring short-term symptom changes monitored outcomes related to physical discomfort. Research has tracked outcomes reflecting daily functioning or activity level during periods of heightened symptom activity.


Evidence for Use in Appetite Stimulation

Research explored the use of Cypromin for appetite stimulation and addressing low body mass in specialized RCTs and subsequent meta-analyses. Studies explored the drug in research contexts involving functional imbalance in specific patient cohorts. Research examined outcomes related to caloric intake and the resulting changes in body weight or body mass index (BMI).

Findings describe patterns observed in the studies regarding weight changes, specifically indicating patterns related to body mass changes in populations such as pediatric patients with growth concerns and adults dealing with significant appetite loss. However, the evidence is limited and heterogeneous because research explored many different underlying causes of appetite loss, indicating variability across the different underlying causes of appetite loss.

Research Design: Tracking Weight and Calorie Intake

This sub-section describes how studies were designed to measure changes in clinical metrics like body mass index (BMI) and calculated caloric consumption over the observation periods. Research focused on body mass and nutritional markers in groups of patients with appetite loss.

Key Studies & References Health Canada labelling standards for Cyproheptadine

Frequently Asked Questions (FAQ)

Common questions about Cypromin (FAQ)

Q: How long does it take for Cypromin to start working?

According to the official product information, the onset of action is generally observed within 15 to 60 minutes after the medicine is taken. This time frame indicates when the effects of the drug are expected to begin, based on clinical pharmacology.


Q: What happens if I forget to take Cypromin one day?

Official patient guidance for a missed dose advises that if the dose is remembered shortly after the scheduled time, it may be taken. However, if it is close to the time for the next scheduled dose, the missed dose is typically omitted, following the official administration instructions.


Q: Does Cypromin cause weight gain or weight loss?

Official labeling lists an increase in appetite and associated weight gain as potential adverse reactions. This is thought to be related to the medicine’s function as a serotonin antagonist. Weight loss is not listed as a commonly reported effect in the product information.


Q: Are the side effects of Cypromin permanent?

The official product information describes side effects such as sedation and sleepiness as transient, meaning they may lessen or disappear with continued use. The reversibility or long-term nature of other, less common serious adverse effects is not uniformly classified on the official label.


Q: Do I need to change my diet while taking Cypromin?

Administration instructions indicate that the medicine may be taken with or without food. No mandatory dietary changes or food restrictions are described in the official patient information beyond this timing flexibility.


Q: Is it normal to feel tired when starting Cypromin?

Yes, regulatory labeling lists sedation and sleepiness (somnolence) as the most frequently reported adverse reactions. These effects are especially common when beginning administration and relate to the medicine's documented effects on the central nervous system.


Q: Can older adults use Cypromin safely?

Use is formally contraindicated in elderly or debilitated patients. These warnings reflect the increased documented potential for certain adverse effects, including dizziness, sedation, and low blood pressure, in older individuals.


Q: Does Cypromin interact with vitamins or herbal supplements?

The official label specifically warns against interactions with certain drug classes and alcohol. The professional monograph advises that potential effects of co-administration with other substances, including supplements, are not always thoroughly studied or documented. Caution is warranted when combining prescription medicines with any non-prescribed substance.


Q: Can Cypromin affect my sleep schedule?

Yes, official documents state that the most commonly reported side effects include sleepiness (somnolence) and sedation. Because these effects are documented to affect alertness, they can influence the daily sleep-wake cycle.


Q: Is Cypromin a type of antidepressant?

No, the medicine is pharmacologically classified as a first-generation antihistamine and a serotonin antagonist. While its action involves the serotonin system, it is not classified as an antidepressant.


Q: Can Cypromin be used for anything other than what the doctor prescribed?

Regulatory documents only detail the approved indications for which the medicine has established safety and effectiveness. Any information regarding unapproved uses is outside the scope of official regulatory labeling.


Q: Is Cypromin the same as other similar medicines I've heard of?

Cypromin has a specific pharmacological profile. It is classified as a first-generation antihistamine that is also a potent serotonin antagonist. This dual classification makes it pharmacologically distinct from other similar agents.


Q: Why do some people say Cypromin made them feel dizzy?

Dizziness is a documented adverse reaction that is common with the use of this medicine. This effect is listed in regulatory documents and is often related to the drug's actions on the central nervous system.


Q: Can Cypromin be crushed or split in half?

The official prescribing information provides instructions for using the tablet and syrup forms as dispensed. Alteration to the tablet form, such as crushing or splitting, should only be done if explicitly detailed in the labeled administration instructions.


Q: What kind of studies have been done on Cypromin?

Research evidence for Cypromin primarily draws from established research designs, including Randomized Controlled Trials (RCTs) and systematic reviews (meta-analyses). These studies have been conducted in both adult and pediatric populations.


Q: What happens if I accidentally take too much Cypromin?

The official label includes a section on overdosage, which describes potential signs such as severe sedation, central nervous system depression or excitation (especially in children), and severe anticholinergic effects. If an overdosage is suspected, seeking emergency medical attention is necessary.


Q: Is Cypromin addictive or habit-forming?

Regulatory documents do not classify Cypromin as a controlled substance. The official label does not describe it as having a potential for abuse or habit formation.


Q: When is the best time of day to take Cypromin?

Official instructions mandate administration in divided doses throughout the day. Because sedation is a frequently reported side effect, healthcare providers often suggest a timing for doses that accounts for the potential for drowsiness.


Q: Why is Cypromin sometimes described as an 'off-label' medication?

The medicine is officially approved for allergic conditions. Its unique secondary function as a potent serotonin antagonist provides a pharmacological basis for its exploration in other areas, which can lead to its use being referred to by descriptive terms related to uses beyond its approved indication.


Q: Is there a generic version of Cypromin available?

Yes, the active ingredient in Cypromin is Cyproheptadine hydrochloride, which is the generic name for the medicine. Generic versions of medications typically contain the same active ingredient.


Q: What should I do if my side effects don't go away while on Cypromin?

Official patient information instructs that if side effects persist, worsen, or cause distress, the official instruction is to discuss these effects with a healthcare provider.


Q: Is Cypromin considered a controlled substance?

No, the medicine is not classified as a controlled substance by regulatory bodies such as the Drug Enforcement Administration (DEA) in the United States. It is a prescription-only medication.


Q: How is Cypromin eliminated from the body?

According to the clinical pharmacology section of the professional monograph, the active ingredient is extensively metabolized by the body. The resulting compounds are then eliminated primarily through excretion in the urine and, to a lesser extent, in the feces.


Q: Is Cypromin safe for children?

Safety and efficacy are established for children aged 2 years and older. However, the medicine is formally contraindicated in infants who are premature or newborn due to increased risk factors in that population.


Q: Why does the official document list so many possible side effects?

Official documents list a comprehensive range of side effects because regulatory bodies require the inclusion of all adverse events reported during clinical trials and post-marketing surveillance. This ensures that patients and prescribers are fully informed of all observed outcomes, regardless of how common or rare they may be.


Q: How soon after stopping Cypromin can I start taking another medication?

The time required for the medicine to be completely eliminated from the body depends on the half-life of the drug, which is detailed in the clinical pharmacology section of the professional monograph. The necessity of a waiting period before starting another medication is often determined by the potential for drug interaction.


Q: Why is Cypromin sometimes given with other medicines?

The medicine is sometimes administered with other agents, though specific warnings exist for co-administration. Official labeling warns against combining it with other central nervous system depressants and anticholinergic agents due to the risk of additive effects, such as increased drowsiness.


Q: How reliable is the research evidence for Cypromin's main use?

Evidence for the approved uses of Cypromin is drawn from research designs, including randomized controlled trials (RCTs) and systematic reviews. Official documents note that comparative evidence against newer drugs, particularly second-generation antihistamines, may be limited in the research base.


Q: Can Cypromin be taken on an empty stomach?

Yes, the official administration instructions state that the medication may be taken with or without food. This indicates that it can be administered on an empty stomach if necessary.


Q: Does Cypromin have known interactions with common cold medicines?

The official interactions section warns against co-administration with other central nervous system (CNS) depressants and anticholinergic agents. These are common components in many over-the-counter cold and flu preparations; due to this potential, caution is recommended.


Q: Does Cypromin have a black box warning from the FDA?

The official FDA Prescribing Information for Cyproheptadine, the active ingredient in Cypromin, does not contain a Boxed Warning (Black Box Warning). This warning is reserved for serious safety concerns with certain medicines.

How should Cypromin be stored and disposed of?

How to Store and Dispose of Cypromin

Official labeling requires Cyproheptadine Hydrochloride (Cypromin) to be stored at Controlled Room Temperature, defined as 20^circ to 25 C (68^circ to 77 F), with excursions permitted up to 30 C. The medication must be protected from excess heat and moisture; the oral solution requires a tight, light-resistant container. Both tablets and syrup must be dispensed in containers with a child-resistant closure and must be kept out of the sight and reach of children.

All unused medication must be discarded after the expiration date. Disposal of expired or unused product must be completed according to local regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Cypromin found in:

A-Z Index: